UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 275

Sortiert nach

P319 Tolérance de la linagliptine chez 8 778 patients diabétiques de type 2 (DT2): analyse des données regroupées de 23 études cliniques randomisées et contrôlées par placebo

Diabetes & metabolism, 2015-03, Vol.41, p.A114-A114

2015

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment

Diabetes, obesity & metabolism, 2014-03, Vol.16 (3), p.215-222

2014

Volltextzugriff (PDF)

Pregnancy outcomes in women with gestational diabetes mellitus diagnosed according to the WHO-2013 and WHO-1999 diagnostic criteria: a multicentre retrospective cohort study

BMC pregnancy and childbirth, 2018-05, Vol.18 (1), p.152-152, Article 152

2018

Volltextzugriff (PDF)

Selective hydrogenolysis of glycerol over Ir-Ni bimetallic catalysts

Catalysis today, 2017-07, Vol.289, p.302-308

2017

Volltextzugriff (PDF)

VEGF Levels in Plasma in Relation to Platelet Activation, Glycemic Control, and Microvascular Complications in Type 1 Diabetes

Diabetes care, 2013-06, Vol.36 (6), p.1629-1634

2013

Volltextzugriff (PDF)

Effet d’empagliflozine sur le changement (aggravation/amélioration) de groupe de risque d’IRC selon KDIGO : évalué dans EMPA-REG-OUTCOME

Néphrologie & thérapeutique, 2022-09, Vol.18 (5), p.355

2022

Volltextzugriff (PDF)

Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment

Diabetes, obesity & metabolism, 2014-02, Vol.16 (2), p.118-123

2014

Volltextzugriff (PDF)

Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers

Diabetes, obesity & metabolism, 2013-04, Vol.15 (4), p.316-323

2013

Volltextzugriff (PDF)

Médiateurs de l’effet du traitement par empagliflozine sur les résultats rénaux dans l’essai EMPA-REG OUTCOME

Néphrologie & thérapeutique, 2021-09, Vol.17 (5), p.339-339

2021

Volltextzugriff (PDF)

EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR MORTALITY BY PREVALENT OR INCIDENT HEART FAILURE IN THE EMPA-REG OUTCOME TRIAL

Canadian journal of cardiology, 2016-10, Vol.32 (10), p.S90-S91

2016

Volltextzugriff (PDF)

EFFECTS OF EMPAGLIFLOZIN ON OVERALL HEART FAILURE BURDEN IN EMPA-REG OUTCOME

Canadian journal of cardiology, 2016-10, Vol.32 (10), p.S175-S176

2016

Volltextzugriff (PDF)

Social Work and Obesity

Critical social work, 2020-10, Vol.21 (2), p.57-72

2020

Volltextzugriff (PDF)

Can Reptiles Use Nest Site Choice Behavior to Counter Global Warming Effects on Developing Embryos? Potential Climate Responses in a Turtle

Frontiers in ecology and evolution, 2022-03, Vol.10

2022

Volltextzugriff (PDF)

EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK

Canadian journal of cardiology, 2016-10, Vol.32 (10), p.S122-S123

2016

Volltextzugriff (PDF)

Green urine, but no infection

The Lancet (British edition), 2009-10, Vol.374 (9700), p.1566-1566

2009

Volltextzugriff (PDF)

History matters more when explaining genetic diversity within the context of the core-periphery hypothesis

Molecular ecology, 2015-08, Vol.24 (16), p.4323-4336

2015

Volltextzugriff (PDF)

Geophysiology of Wood Frogs: Landscape Patterns of Prevalence of Disease and Circulating Hormone Concentrations across the Eastern Range

Integrative and comparative biology, 2015-10, Vol.55 (4), p.602-617

2015

Volltextzugriff (PDF)

Reduced immune function predicts disease susceptibility in frogs infected with a deadly fungal pathogen

Conservation physiology, 2016-04, Vol.4 (1), p.cow011-cow011

2016

Volltextzugriff (PDF)

Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes

European heart journal, 2021-10, Vol.42 (Supplement_1)

2021

Volltextzugriff (PDF)

Effects of linagliptin vs glimepiride stratified by prior insulin secretagogue use in the cardiovascular outcome study of linagliptin versus glimepiride in type 2 diabetes (CAROLINA) trial

European heart journal, 2020-11, Vol.41 (Supplement_2)

2020

Volltextzugriff (PDF)

Analysis of first plus recurrent cardiovascular (CV) and hospitalisation events in the CAROLINA trial

European heart journal, 2020-11, Vol.41 (Supplement_2)

2020

Volltextzugriff (PDF)

Consistent cardiovascular (CV) benefit of empagliflozin over the spectrum of CV risk factor control in EMPA-REG OUTCOME

Metabolism, clinical and experimental, 2020-03, Vol.104, p.154125, Article 154125

2020

Volltextzugriff (PDF)

Hydrogenolysis of glycerol over ZSM-5 supported ruthenium and copper catalysts: Structural study and effects in reaction

Catalysis today, 2023-07, Vol.419, p.114161, Article 114161

2023

Volltextzugriff (PDF)

ASSOCIATION OF KIDNEY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL

Canadian journal of cardiology, 2021-10, Vol.37 (10), p.S62-S63

2021

Volltextzugriff (PDF)

EMPAGLIFLOZIN (EMPA) REDUCES HEART FAILURE OUTCOMES IRRESPECTIVE OF BLOOD PRESSURE (BP), LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) AND HBA1C CONTROL

Canadian journal of cardiology, 2017-10, Vol.33 (10), p.S172-S172

2017

Volltextzugriff (PDF)

1 – 25 von 275

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(235)
Mit Volltextzugriff
(246)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(192)
Life Sciences & Biomedicine
(137)
Humans
(88)
Male
(59)
Female
(56)
Biological And Medical Sciences
(55)
Physical Sciences
(42)
Adult
(38)
Technology
(36)
Medical Sciences
(34)
Middle Aged
(32)
Animals
(31)
Engineering
(27)
Fundamental And Applied Biological Sciences. Psychology
(22)
Aged
(21)
Chemistry
(21)
Biotechnology
(18)
Exact Sciences And Technology
(18)
Biotechnology & Applied Microbiology
(17)
Diabetes
(15)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

P319 Tolérance de la linagliptine chez 8 778 patients diabétiques de type 2 (DT2): analyse des données regroupées de 23 études cliniques randomisées et contrôlées par placebo

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment

Pregnancy outcomes in women with gestational diabetes mellitus diagnosed according to the WHO-2013 and WHO-1999 diagnostic criteria: a multicentre retrospective cohort study

Selective hydrogenolysis of glycerol over Ir-Ni bimetallic catalysts

VEGF Levels in Plasma in Relation to Platelet Activation, Glycemic Control, and Microvascular Complications in Type 1 Diabetes

Effet d’empagliflozine sur le changement (aggravation/amélioration) de groupe de risque d’IRC selon KDIGO : évalué dans EMPA-REG-OUTCOME

Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment

Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers

Médiateurs de l’effet du traitement par empagliflozine sur les résultats rénaux dans l’essai EMPA-REG OUTCOME

EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR MORTALITY BY PREVALENT OR INCIDENT HEART FAILURE IN THE EMPA-REG OUTCOME TRIAL

EFFECTS OF EMPAGLIFLOZIN ON OVERALL HEART FAILURE BURDEN IN EMPA-REG OUTCOME

Social Work and Obesity

Can Reptiles Use Nest Site Choice Behavior to Counter Global Warming Effects on Developing Embryos? Potential Climate Responses in a Turtle

EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK

Green urine, but no infection

History matters more when explaining genetic diversity within the context of the core-periphery hypothesis

Geophysiology of Wood Frogs: Landscape Patterns of Prevalence of Disease and Circulating Hormone Concentrations across the Eastern Range

Reduced immune function predicts disease susceptibility in frogs infected with a deadly fungal pathogen

Impact of changes in weight and haematocrit on the reduction in systolic office and ambulatory blood pressure with empagliflozin in patients with type 2 diabetes

Effects of linagliptin vs glimepiride stratified by prior insulin secretagogue use in the cardiovascular outcome study of linagliptin versus glimepiride in type 2 diabetes (CAROLINA) trial

Analysis of first plus recurrent cardiovascular (CV) and hospitalisation events in the CAROLINA trial

Consistent cardiovascular (CV) benefit of empagliflozin over the spectrum of CV risk factor control in EMPA-REG OUTCOME

Hydrogenolysis of glycerol over ZSM-5 supported ruthenium and copper catalysts: Structural study and effects in reaction

ASSOCIATION OF KIDNEY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL

EMPAGLIFLOZIN (EMPA) REDUCES HEART FAILURE OUTCOMES IRRESPECTIVE OF BLOOD PRESSURE (BP), LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) AND HBA1C CONTROL

Suchergebnisse filtern